[go: up one dir, main page]

BR0313424A - Forma de dosagem e processo para a preparação de uma forma de dosagem - Google Patents

Forma de dosagem e processo para a preparação de uma forma de dosagem

Info

Publication number
BR0313424A
BR0313424A BR0313424-5A BR0313424A BR0313424A BR 0313424 A BR0313424 A BR 0313424A BR 0313424 A BR0313424 A BR 0313424A BR 0313424 A BR0313424 A BR 0313424A
Authority
BR
Brazil
Prior art keywords
dosage form
active ingredient
preparing
release active
immediate release
Prior art date
Application number
BR0313424-5A
Other languages
English (en)
Other versions
BR0313424B1 (pt
BRPI0313424B8 (pt
Inventor
Navin Vaya
Sunil Sadanand Nadkarni
Rajesh Singh Karan
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR0313424A publication Critical patent/BR0313424A/pt
Publication of BR0313424B1 publication Critical patent/BR0313424B1/pt
Publication of BRPI0313424B8 publication Critical patent/BRPI0313424B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMA DE DOSAGEM E PROCESSO PARA A PREPARAçãO DE UMA FORMA DE DOSAGEM". A presente invenção refere-se a uma forma de dosagem compreendendo um ingrediente ativo de alta solubilidade e de alta dose com liberação modificada e um ingrediente ativo de baixa dose com liberação imediata onde a razão de peso do ingrediente ativo de liberação imediata e do ingrediente ativo de liberação modificada é a partir de 1:10 a 1: 15000 e o peso do ingrediente ativo de liberação imediata é a partir de 500 mg a 1500 mg. A presente invenção também refere-se a um processo para a preparação da formulação.
BRPI0313424A 2002-08-05 2003-08-01 forma de dosagem e processo para a preparação de uma forma de dosagem BRPI0313424B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN699MU2002 2002-08-05
IN697MU2002 2002-08-05
IN80MU2003 2003-01-22
IN82MU2003 2003-01-22
PCT/IN2003/000262 WO2004012700A2 (en) 2002-08-05 2003-08-01 Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release

Publications (3)

Publication Number Publication Date
BR0313424A true BR0313424A (pt) 2005-06-14
BR0313424B1 BR0313424B1 (pt) 2017-10-31
BRPI0313424B8 BRPI0313424B8 (pt) 2021-05-25

Family

ID=31499436

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313424A BRPI0313424B8 (pt) 2002-08-05 2003-08-01 forma de dosagem e processo para a preparação de uma forma de dosagem

Country Status (5)

Country Link
US (3) US7985422B2 (pt)
EP (1) EP1528917B1 (pt)
AU (1) AU2003274681A1 (pt)
BR (1) BRPI0313424B8 (pt)
WO (1) WO2004012700A2 (pt)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
EP1623703B1 (en) 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
HU230875B1 (hu) 2000-10-30 2018-11-29 Euro-Celtique S.A. Szabályozott hatóanyag-leadású hidrokodon készítmények
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
ES2627842T3 (es) * 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Formas de dosificación de liberación controlada
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
DE10307728B4 (de) * 2003-02-24 2005-09-22 Clariant Gmbh Korrosions-und Gashydratinhibitoren mit verbesserter Wasserlöslichkeit und erhöhter biologischer Abbaubarkeit und derartige Verbindungen
DE602004003577T2 (de) * 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2005065639A2 (en) * 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
US20080181946A1 (en) * 2004-05-14 2008-07-31 Braj Bhushan Lohray Controlled Release Delivery System For Metformin
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
AR050615A1 (es) * 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
WO2006031024A1 (en) 2004-09-15 2006-03-23 Gl Pharmtech Corp. A sustained-release tablet containing doxazosin mesylate
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
GB0502479D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
WO2006086856A1 (en) * 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
US7348027B2 (en) * 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
US20100087546A1 (en) * 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
US20060264458A1 (en) * 2005-05-03 2006-11-23 Jie Du Quinine dosage forms and methods of use thereof
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
KR20080031208A (ko) * 2005-05-25 2008-04-08 트랜스셉트 파마슈티칼스, 인코포레이티드 야반 불면증을 치료하기 위한 고체 조성물 및 방법
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7544373B2 (en) 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
AU2006283211B2 (en) 2005-08-22 2012-06-21 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
RU2385712C2 (ru) * 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
EP2324838A1 (en) 2005-09-12 2011-05-25 Abela Pharmaceuticals, Inc. Compositions Comprising Dimethyl Sulfoxide (DMSO)
US7955418B2 (en) * 2005-09-12 2011-06-07 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
US8480797B2 (en) * 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
DE102005054610B4 (de) * 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
AU2006318447A1 (en) * 2005-11-21 2007-05-31 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Methods of using small molecule compounds for neuroprotection
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
US7427414B2 (en) * 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US7811549B2 (en) 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
WO2008012603A1 (en) * 2006-07-26 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CN105439877B (zh) * 2006-07-26 2019-07-23 于崇曦 带正电荷的水溶性二氟尼柳及相关化合物的前药
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
AU2007286659A1 (en) * 2006-08-23 2008-02-28 Wyeth 8-Hydroxyquinoline Compounds and methods thereof
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation
US20110165236A1 (en) * 2006-09-22 2011-07-07 Biokey, Inc. Controlled release hydrogel formulation
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
KR100822180B1 (ko) * 2006-11-22 2008-04-16 광동제약 주식회사 마진돌 함유 정제의 안정화 방법
US20080140450A1 (en) * 2006-11-28 2008-06-12 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with norfluoxetine
WO2008067549A2 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized zolpidem pharmaceutical compositions
CN102218044A (zh) * 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
CA2673214A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
US20100099693A1 (en) * 2007-01-16 2010-04-22 Johan Raud New combination for use in the treatment of inflammatory disorders
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
JPWO2008111674A1 (ja) * 2007-03-15 2010-06-24 東洋紡績株式会社 口腔粘膜貼付ブプレノルフィン製剤の製造方法
US20100143471A1 (en) * 2007-03-21 2010-06-10 Lupin Limited Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
WO2008121107A1 (en) * 2007-04-02 2008-10-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance
DK2170826T3 (da) 2007-06-04 2022-07-11 Techfields Inc Nsaia-pro-lægemidler med meget høje hud- og membranpenetrationshastigheder og deres nye medicinske anvendelser
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2009007680A2 (en) 2007-07-11 2009-01-15 Cardoz Ab Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
KR20100119578A (ko) * 2008-02-28 2010-11-09 노파르티스 아게 발사르탄 고체 경구 투여 형태 및 이러한 제형물의 제조 방법
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
CN101550162B (zh) * 2008-04-03 2015-11-25 北京华昊中天生物技术有限公司 福司曲星衍生物及其药用用途
ES2395002T3 (es) * 2008-04-07 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
EP2278978B1 (en) * 2008-05-28 2015-09-02 ReveraGen BioPharma, Inc. Non-hormonal steroid modulators of nf-kb for treatment of disease
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
BRPI0913425A2 (pt) * 2008-06-02 2015-11-24 Reddys Lab Ltd Dr formulações de niacina com liberação modificada
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
WO2010025135A2 (en) * 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
US20110144055A1 (en) * 2008-09-04 2011-06-16 Rozmanith Anthony I Health Care
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US8753677B2 (en) 2008-09-16 2014-06-17 The Invention Science Fund I, Llc Ex vivo modifiable multiple medicament final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
US20100069887A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Multiple chamber ex vivo adjustable-release final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068233A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Modifiable dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US8198268B2 (en) * 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
KR20200022525A (ko) 2008-12-04 2020-03-03 충시 위 고투과력을 가진 조성물 및 이의 적용
WO2010064100A1 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Baclofen gastroretentive drug delivery system
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
KR101697800B1 (ko) * 2009-02-13 2017-01-18 로마크 레버러토리즈, 엘.씨. 니타족사니드의 서방성 제약 제형
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2010134938A1 (en) * 2009-05-18 2010-11-25 Dr. Reddy's Laboratories Ltd. Modified release niacin pharmaceutical formulations
ES2627655T3 (es) 2009-05-19 2017-07-31 Neuroderm Ltd Composiciones para la administración continua de inhibidores de DOPA descarboxilasa
KR20120030112A (ko) * 2009-06-05 2012-03-27 타우 쎄라퓨틱스 엘엘씨 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
AU2010313253B2 (en) 2009-10-30 2015-02-19 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
CN108785654A (zh) 2009-11-23 2018-11-13 丘比斯特制药有限责任公司 脂肽组合物和相关方法
CN106389381A (zh) 2009-12-02 2017-02-15 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
EP2514422B1 (en) * 2009-12-18 2016-08-10 Mitsubishi Tanabe Pharma Corporation Elution stabilized teneligliptin preparation
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
CA2787673A1 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
AU2011232408B2 (en) * 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
WO2011143120A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholres i stant metoprolol - containing extended - release oral dosage forms
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US20120052011A1 (en) * 2010-08-24 2012-03-01 Canon Kabushiki Kaisha Composition and a method for producing contrast agent using the composition
WO2012028922A2 (en) * 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
SMT201800145T1 (it) 2010-11-15 2018-05-02 Neuroderm Ltd Somministrazione continua di l-dopa, di inibitori della dopa decarbossilasi, di inibitori della catecol-o-metil trasferasi e composizioni per essa
US8597683B2 (en) 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
CA2827336C (en) 2011-02-23 2016-01-26 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
EP2709453B1 (en) 2011-05-16 2019-10-23 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
US9532984B2 (en) * 2011-06-10 2017-01-03 The Translational Genomics Research Institute Therapeutic combination for cancer treatment
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2768499A4 (en) 2011-10-17 2015-08-26 Univ Vanderbilt INDOMETHACIN ANALOGUE FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER
US9226891B2 (en) 2011-10-28 2016-01-05 Vitalis Llc Anti-flush compositions
US9717678B2 (en) * 2011-11-06 2017-08-01 Murty Pharmaceuticals, Inc. Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
JP6152387B2 (ja) * 2011-12-12 2017-06-21 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｉ型およびｉｉ型糖尿病の処置
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US20130183263A1 (en) * 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
MX377674B (es) * 2012-03-19 2025-03-11 Althera Life Sciencies Llc Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.
EP2836234B1 (en) 2012-04-12 2019-06-12 Yale University Vehicles for controlled delivery of different pharmaceutical agents
CN104040347B (zh) * 2012-04-30 2016-06-15 科学与工业研究会 用于呼吸中的丙酮检测的传感器组合物
US9999674B2 (en) 2012-06-05 2018-06-19 Neuroderm, Ltd. Compositions comprising apomorphine and organic acids and uses thereof
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
RU2521572C1 (ru) * 2012-12-21 2014-06-27 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма фенбуфена
WO2014122671A2 (en) * 2013-02-08 2014-08-14 Hetero Research Foundation Solid oral compositions of saxagliptin
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2014203140A1 (en) 2013-06-22 2014-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3087082B1 (en) * 2013-12-23 2023-10-11 SOCPRA Sciences et Génie s.e.c. Atp synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN111956653B (zh) 2014-05-08 2023-06-30 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
EP2959887B1 (de) * 2014-06-26 2018-11-14 Hennig Arzneimittel GmbH&Co. Kg Arzneimittel zur Behandlung von Schwindel verschiedener Genese
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
CN104523636B (zh) * 2014-12-25 2017-07-18 昆明振华制药厂有限公司 一种呋喃唑酮缓释片及其制备方法
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
KR101663543B1 (ko) * 2015-07-29 2016-10-07 고려대학교 산학협력단 부스피론 유도체 및 이를 함유하는 약학 조성물
US11648212B2 (en) * 2016-02-03 2023-05-16 Intelgenx Corp. Loxapine film oral dosage form
AU2017295866A1 (en) 2016-07-14 2019-01-17 Achaogen, Inc. Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
CN109640991A (zh) 2016-07-29 2019-04-16 詹森药业有限公司 治疗前列腺癌的方法
EP3518910A4 (en) * 2016-09-30 2020-11-04 Xenamed Corporation COMPOSITIONS OF MIDODRINE AND THEIR METHODS OF USE
KR20190074310A (ko) * 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US11478467B2 (en) * 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
WO2018213713A1 (en) * 2017-05-19 2018-11-22 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
WO2019014201A1 (en) * 2017-07-10 2019-01-17 Apicore Us Llc MOLINDONE COMPOSITIONS WITH EXTENDED RELEASE
IL272834B2 (en) 2017-08-24 2024-08-01 Adamas Pharma Llc Amantadine compositions, preparations thereof, and methods of use
MY204588A (en) 2017-10-25 2024-09-05 Chiesi Farm Spa Delayed release deferiprone tablets and methods of using the same
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
EP3727347A4 (en) * 2017-12-22 2021-10-20 Xenamed Corp. LONG-RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
EP3546589B1 (de) * 2018-03-29 2022-08-10 Evonik Operations GmbH Verfahren zur herstellung von sphingolipiden
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
WO2020018888A1 (en) 2018-07-20 2020-01-23 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
CA3112190A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
EP3852723B1 (en) 2018-09-20 2025-11-05 ACADIA Pharmaceuticals Inc. Stable intranasal formulations of carbetocin
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
KR20200077911A (ko) * 2018-12-21 2020-07-01 (주)유케이케미팜 잘토프로펜 함유 서방성 의약 조성물
US10869860B2 (en) * 2018-12-28 2020-12-22 Vividion Therapeutics, Inc. Cereblon modulators and uses thereof
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
CN111000844B (zh) * 2019-12-19 2022-06-28 浙江立恩生物科技有限公司 一种治疗流感病毒感染的药物
CN110903247B (zh) * 2019-12-23 2022-04-05 常州齐晖药业有限公司 一种大幅降低奥芬达唑杂质b的制备方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
CN112089823B (zh) * 2020-09-25 2024-02-06 珠海中科先进技术研究院有限公司 一种短梗霉素a和制霉菌素组合物及其复合软膏、凝胶剂以及喷剂
WO2022091065A1 (ko) * 2020-11-02 2022-05-05 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
CN113069421A (zh) * 2021-03-29 2021-07-06 海南锦瑞制药有限公司 注射用兰索拉唑
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102762725B1 (ko) * 2022-03-24 2025-02-06 주식회사 케이에스비튜젠 레보드로프로피진을 유효성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
CN116407557A (zh) * 2023-05-29 2023-07-11 四川大学华西医院 一种防治出血性脑卒中的药物组合物及其应用
CN117607311B (zh) * 2024-01-19 2024-03-29 地奥集团成都药业股份有限公司 一种盐酸贝那普利对映异构体的检测方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) * 1958-08-04 1962-08-07 Wander Company Medicinal tablet
US3336200A (en) 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
CA2217233A1 (en) 1995-04-03 1996-10-10 Chugai Seiyaku Kabushiki Kaisha Sucralfate containing pharmaceutical composition
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US6756056B2 (en) 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
ID26082A (id) * 1998-03-19 2000-11-23 Briston Myers Squib Company Sistem pengiriman lepas terkendali dwifasa untuk zat-zat farmasi kelarutan tinggi dan metodenya
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion

Also Published As

Publication number Publication date
WO2004012700A3 (en) 2004-04-01
US20040096499A1 (en) 2004-05-20
US7985422B2 (en) 2011-07-26
EP1528917B1 (en) 2013-06-19
AU2003274681A8 (en) 2004-02-23
EP1528917A2 (en) 2005-05-11
US20060153916A1 (en) 2006-07-13
AU2003274681A1 (en) 2004-02-23
BR0313424B1 (pt) 2017-10-31
BRPI0313424B8 (pt) 2021-05-25
US20060024365A1 (en) 2006-02-02
WO2004012700A2 (en) 2004-02-12
US8263125B2 (en) 2012-09-11

Similar Documents

Publication Publication Date Title
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BR0309528A (pt) Comprimido com alta carga de droga
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
BR0008059A (pt) Composições de valdecoxib
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BR0210261A (pt) Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
BR0214497A (pt) Composição farmacêutica que compreende um agonista do receptor 5ht1
BR0115989A (pt) Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
RU2010107177A (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств
BR0208463A (pt) Compostos farmaceuticamente ativos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/08/2023.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2786 DE 28/05/2024 POR TER SIDO INDEVIDA.